Level Bio (LEVBIO) Q1 2026 earnings summary

Executive summary

• Net sales increased by 15% year-over-year to 8,995 KSEK for Q1 2026, with a strong gross margin of 52%.

• The quarter marked a strategic shift with the divestment of subsidiary CyberGene, completed after the period, strengthening the financial position and clarifying the business focus on advanced diagnostics distribution via Techtum Lab.

• Excluding depreciation, the result turned positive; depreciation related to CyberGene will no longer impact results from Q2 2026.

Financial highlights

• Net sales: 8,995 KSEK (up 15% year-over-year from 7,808 KSEK).

• Gross margin: 52% (50% last year).

• Operating result: -117 KSEK (improved from -895 KSEK year-over-year).

• Result after tax: -169 KSEK (improved from -836 KSEK year-over-year).

• Cash flow: -1,023 KSEK (266 KSEK last year); cash and equivalents at period end: 1,461 KSEK.

Outlook and guidance

• Future quarters will reflect a lower revenue base due to the CyberGene divestment but a clearer business model focused on distribution.

• Strategic review underway to optimize long-term positioning, capital allocation, and growth strategy.

• Emphasis on increasing recurring revenue in distribution for greater predictability and stability.